Executive Order 13367: United States-Mexico Border Health Commission
President: George W. Bush
Designated the bilateral U.S.–Mexico Border Health Commission under the International Organizations Immunities Act, with a narrow entry and departure privilege.
Status: In effect. Is Executive Order 13367 still in effect? Yes. Executive Order 13367 remains in effect. See Federal Register record.
What does Executive Order 13367 do?
EO 13367 designated that commission as a public international organization. It extended only specified entry and departure privileges to members and employees of its Mexican section, expressly excluding other privileges under the Act. CDC identified the commission as a partner in its Binational Border Infectious Disease Surveillance program in January 2026.
Before and after
Before the order
The U.S.–Mexico Border Health Commission Act authorized U.S. participation in a bilateral border-health body.
After the order
EO 13367 designated that commission as a public international organization. It extended only specified entry and departure privileges to members and employees of its Mexican section, expressly excluding other privileges under the Act.
CDC identified the commission as a partner in its Binational Border Infectious Disease Surveillance program in January 2026.
What did the signed order change?
The U.S.–Mexico Border Health Commission Act authorized U.S. participation in a bilateral border-health body. EO 13367 designated that commission as a public international organization. It extended only specified entry and departure privileges to members and employees of its Mexican section, expressly excluding other privileges under the Act.
What happened later?
CDC — Binational Border Infectious Disease Surveillance documents this later development: CDC identified the commission as a partner in its Binational Border Infectious Disease Surveillance program in January 2026.
What does that evidence establish?
Only 22 U.S.C. 288d(a) entry/departure privileges for the Mexican section were extended; the signed order expressly withheld other IOIA privileges. CDC’s later partnership shows activity, not that the designation itself produced a measurable health outcome. The order did not grant blanket immunity or establish the CDC surveillance program. The signed order controls its original terms.
Who had to do what
| Agency / office | Action | Timing / position |
|---|---|---|
| U.S.–Mexico Border Health Commission and U.S. agencies | Coordinated border-health work within the commission’s statutory remit | Under the signed order and governing law |
What happened next
EO 13367 signed.
CDC identified the commission as a partner in its Binational Border Infectious Disease Surveillance program in January 2026.
Legal and source detail
How it works legally
Only 22 U.S.C. 288d(a) entry/departure privileges for the Mexican section were extended; the signed order expressly withheld other IOIA privileges. CDC’s later partnership shows activity, not that the designation itself produced a measurable health outcome.
Sources by type
If a source is unavailable, first check the cited publisher or another official repository. The cited publisher remains the authority.
Primary and official sources
Orders, laws, court records and official implementation material.
- GovInfo — official executive-order record (opens in a new tab) Official record
How we checked this
Last checked against the sources above on September 26, 2026. How we research →